Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Depreciation: 2022-2025

Historic Accumulated Depreciation for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Sep 2025 value amounting to $1.5 million.

  • Orchestra BioMed Holdings' Accumulated Depreciation rose 26.99% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 26.99%. This contributed to the annual value of $1.3 million for FY2024, which is 24.81% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Accumulated Depreciation of $1.5 million as of Q3 2025, which was up 5.52% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Accumulated Depreciation registered a high of $1.5 million during Q3 2025, and its lowest value of $778,000 during Q4 2022.
  • Its 3-year average for Accumulated Depreciation is $1.2 million, with a median of $1.2 million in 2024.
  • Data for Orchestra BioMed Holdings' Accumulated Depreciation shows a peak YoY spiked of 34.19% (in 2023) over the last 5 years.
  • Orchestra BioMed Holdings' Accumulated Depreciation (Quarterly) stood at $778,000 in 2022, then skyrocketed by 34.19% to $1.0 million in 2023, then grew by 24.81% to $1.3 million in 2024, then climbed by 26.99% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.5 million for Q2 2025, and $1.4 million during Q1 2025.